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Technical Appendix 
 
Methods 
 
Multi-state life tables were used to determine remaining Health-adjusted life 
expectancy (HALE)1,2 of Australian adults aged 35 to 80 years of age in the year 
2000 divided amongst mutually exclusive groups defined by tobacco use: (i) Lifelong 
never smokers and non-snus users; (ii) Current smokers in the year 2000 who 
continue to smoke; (iii) Current smokers in the year 2000 who quit all tobacco use; 
(iv) Current smokers in the year 2000 who switch to snus; and (v) Never smokers in 
the year 2000 who become lifelong snus users. Changes in tobacco use, e.g. 
quitting all tobacco use or starting to use snus, are assumed to be instantaneous in 
the year 2000 with no further changes in tobacco use after this year. The model was 
constructed in Microsoft Excel. 
 
 
Mortality rates by smoking status in the year 2000 
 
As there is no direct source of Australian mortality rates stratified by smoking status 
(never, former, or current smokers), we first estimated tobacco-attributable mortality 
rates for smokers and former smokers combined, for the causes listed in Table 1. 
 
Table 1: Tobacco-related causes of mortality in model3 
Cause ICD-10 code 
Ischemic heart disease I20-I25 
Arterial disease  I70-I79 
Stroke I60-I69, G45 
Other CVD  I26,I27.1,I28,I43-45,I47.0-
I47.1,I47.9,I48,I49.1-.9,I51.0-
I51.4,I52,I77-I84,I86-I97,I98.1-I98.8,I99 
Lung cancer  C33-C34 
Upper aerodigestive cancer C00-C14 
Pancreas cancer  C25 
Bladder cancer  C67 
Kidney cancer  C64-C66,C68 
Chronic obstructive pulmonary disease I27.0,I27.8-I27.9;J40-J44 
Other respiratory disease J30-J39,J47-J99 
 
 
Tobacco-attributable lung cancer rates were estimated as the difference between 
age-and-sex specific lung cancer mortality rates in the Australian population from 
the Australian Bureau of Statistics (ABS), and lung cancer mortality rates in never 
smokers from the American Cancer Society Cancer Prevention Study II (CPS-II) – 
the largest recent cohort study of tobacco exposure and associated health 
outcomes.4  
 
For other tobacco-related cancers and chronic obstructive pulmonary disease 
(COPD) we calculated the smoking impact ratio (SIR; Equation 1), an artificial 
compound prevalence measure of accumulated past exposure to cigarette smoking 
in a population relative to the CPS-II population.5 The SIR represents the proportion 
of equivalent lifelong smokers from CPS-II in the population of interest.  
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Equation 1: 
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Where: 
CLC is the age-sex-specific lung-cancer mortality rate in the Australian 
population for the year 2000 from ABS; 
NLC is the age-sex-specific lung-cancer mortality rate of never-smokers from 
CPS-II; and 
SLC is the age-sex-specific lung cancer mortality rate of lifelong smokers from 
CPS-II. 
 
The SIR was used instead of current prevalence in a population attributable fraction 
(PAF; Equation 2) with relative risks from CPS-II (Table 2) to determine the fraction 
of age-sex-cause-specific mortality rates in the Australian population in the year 
2000 that is attributable to smoking. For all other conditions the prevalence of 
smoking a year prior to the baseline was used, assuming a short lag between 
exposure and outcomes.6 
 
Equation 2: 
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Where: 
p is prevalence (SIR for COPD, cancers); and 
RR is the relative risk in smokers versus the never smokers (from CPS-II; 
Table 2) 
 
Table 2: Relative risks (RR) of tobacco related disease (other than lung 
cancer) in lifelong smokers compared to never smokers from the American 
Cancer Society Cancer Prevention Study II (CPS-II) 7 
  Relative Risk (95% Confidence Interval) 
 Tobacco Related Disease Males Females 
Upper aerodigestive tract 8.1 (5.7-11.7) 6.0 (4.3-8.5) 
Pancreas cancer 2.2 (1.7-2.8) 2.2 (1.8-2.8) 
Urinary bladder cancer 3.0 (2.1-4.3) 2.4 (1.5-4.1) 
Kidney, other urinary cancer 2.5 (1.8-3.6) 1.5 (1.0-2.1) 
Ischemic heart disease    
35-64 years 2.6 (2.4-2.9) 3.2 (2.8-3.6) 
65+ years 1.5 (1.3-1.6) 1.7 (1.6-1.9) 
Stroke    
35-64 years 2.4 (1.8-3.0) 3.8 (3.1-4.7) 
65+ years 1.5 (1.2-1.8) 1.6 (1.4-1.9) 
Arterial disease 3.9 (3.1-4.9) 3.8 (3.1-4.8) 
Other CVD 1.8 (1.6-2.0) 1.7 (1.5-1.9) 
Chronic obstructive pulmonary 
disease 10.8 (8.4-13.9) 12.3 (9.9-15.2) 
Other respiratory disease 1.9 (1.5-2.4) 2.2 (1.7-2.8) 
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The fraction of current mortality rates attributable to tobacco calculated above is a 
function of accumulated risk from past as well as current (year 2000) exposure and 
therefore includes risk attributable to those who currently smoke as well as those 
who are former smokers. To determine the proportion of the tobacco attributable 
mortality rate in current smokers only, we used information on self-reported years 
since quitting in former smokers from The Australian Diabetes, Obesity and Lifestyle 
Study (AusDIAB),8 along with estimates of risk reversal following smoking cessation 
to apportion the tobacco attributable mortality rate between current and former 
smokers (Equation 3). Relative risks of lung cancer, COPD and CVD in former 
smokers compared to current smokers by year since quitting were derived by fitting 
a Weibull distribution to the CPS-II estimates of risk reversal9 (Figures 1 to 3). We 
assumed that risk reversal values for lung cancer were applicable to lung, upper 
aerodigestive, pancreatic, bladder and kidney cancer; and that risk reversal values 
for CVD also applied to respiratory disease other than COPD.10  
 
Equation 3:  
 
( )CSFSFS
CS
CS pRRp
pAF +×=  
 
Where: 
AFCS  is the proportion of the tobacco attributable fraction due to current 
smokers; 
pCS is the prevalence of current smokers; 
pFS  is the prevalence of former smokers; and  
RRFS is the average relative risk of tobacco attributable mortality in former 
smokers compared to current smokers based on reported years since quitting 
smoking.  
 
The proportion of current tobacco attributable mortality due to current smokers by 
cause is shown in Table 3. 
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Figure 1: Risk reversal estimates for lung, upper aerodigestive, 
pancreatic, bladder and kidney cancers 
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Figure 2: Risk reversal estimates for COPD 
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Figure 3: Risk reversal estimates for CVD and Respiratory 
Disease other than COPD 
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Table 3: Proportion of tobacco attributable mortality that is attributable to current smokers, by age, sex and cause 
 Smoking attributable age-specific mortality rate 
Cause of mortality 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 
Males            
Lung cancer 83% 74% 78% 75% 66% 63% 63% 51% 42% 42% 
Upper aerodigestive cancer 83% 74% 78% 75% 66% 63% 63% 51% 42% 42% 
Pancreas cancer 83% 74% 78% 75% 66% 63% 63% 51% 42% 42% 
Kidney cancer 83% 74% 78% 75% 66% 63% 63% 51% 42% 42% 
Bladder cancer 83% 74% 78% 75% 66% 63% 63% 51% 42% 42% 
Ischemic heart disease 86% 79% 83% 83% 75% 73% 73% 71% 57% 58% 
Stroke 86% 79% 83% 83% 75% 73% 73% 71% 57% 58% 
Arterial disease 86% 79% 83% 83% 75% 73% 73% 71% 57% 58% 
Other CVD 86% 79% 83% 83% 75% 73% 73% 71% 57% 58% 
COPD 85% 77% 81% 79% 71% 69% 68% 58% 46% 46% 
Other respiratory disease 86% 79% 83% 83% 75% 73% 73% 71% 57% 58% 
           
Females           
Lung cancer 79% 76% 80% 80% 69% 80% 56% 63% 49% 67% 
Upper aerodigestive cancer 79% 76% 80% 80% 69% 80% 56% 63% 49% 67% 
Pancreas cancer 79% 76% 80% 80% 69% 80% 56% 63% 49% 67% 
Kidney cancer 79% 76% 80% 80% 69% 80% 56% 63% 49% 67% 
Bladder cancer 79% 76% 80% 80% 69% 80% 56% 63% 49% 67% 
Ischemic heart disease 88% 88% 91% 93% 86% 91% 76% 86% 78% 89% 
Stroke 88% 88% 91% 93% 86% 91% 76% 86% 78% 89% 
Arterial disease 88% 88% 91% 93% 86% 91% 76% 86% 78% 89% 
Other CVD 88% 88% 91% 93% 86% 91% 76% 86% 78% 89% 
COPD 76% 74% 81% 84% 70% 81% 57% 71% 58% 77% 
Other respiratory disease 88% 88% 91% 93% 86% 91% 76% 86% 78% 89% 
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Using prevalence of current and never smokers, cause-specific mortality rates and 
attributable fractions derived above, age-sex-specific mortality rates from all causes 
for never smokers and current smokers are shown in Figure 4. 
 
 
 
Mortality risk following smoking cessation 
 
For smokers who quit all tobacco use in each age group in the year 2000, the 
mortality rate at successive ages was determined by the addition of the all-cause 
mortality rate of never-smokers and summing across all tobacco-related causes the 
product of the risk reversal estimates by years since quitting (Figure 1 to 3) and the 
tobacco attributable mortality rates in current smokers. 
 
Mortality risk associated with lifelong snus use 
 
Mortality from lung cancer, oral cancer and heart disease attributable to snus use 
was based on estimates of a panel of international experts11 (Table 4). We 
conservatively assumed that the panel’s estimate for heart disease mortality in snus 
users also applied to mortality due to stroke, arterial disease and other 
cardiovascular diseases. We also assumed that their estimate for oral cancer 
mortality applied to all upper aerodigestive cancers, and cancer of the pancreas, 
bladder and kidney. No excess mortality from COPD or other respiratory diseases 
for snus users was included.12  
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Figure 4: Age-specific mortality rates of smokers and never 
smokers 
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Table 4: Relative risk of tobacco attributable mortality in snus users who 
have never smoked compared to current smokers  
 Relative risk 
Mortality due to: 35-49 year olds ≥ 50 year olds 
all CVDs (including coronary heart 
disease, stroke and arterial disease) 
0.10 0.10 
upper aerodigestive, pancreatic, bladder 
and renal cancer 
0.15 0.30 
Lung cancer 0.02 0.034 
 
These values were applied to the cause-specific tobacco-attributable mortality rate 
in current smokers to obtain the mortality rate attributable to snus in lifelong users 
who had previously never smoked. Figure 5 shows total mortality rates from all 
causes in never smokers compared to lifelong snus users.  
 
 
 
Mortality risk associated with smokers who switch to snus 
 
Current smokers who switch to snus were assumed to have the same excess 
mortality as smokers who quit tobacco entirely (i.e. based on risk reversal estimates 
from CPS-II) and the excess mortality associated with using snus combined in a 
multiplicative formula (Equation 5). 
 
 
 
Age
40 50 60 70 80
M
or
ta
lit
y 
ra
te
 (l
og
 s
ca
le
)
0.001
0.01
0.1 Male lifelong snus user
Female lifelong snus user
Male never tobacco user
Female never tobacco user
 
Figure 5: Mortality rate in lifelong snus users who never 
smoked and never tobacco users 
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 Equation 5: ( )( )( )SnFSCSSnCS RRRRMM −=→ 1-1-1  
 
Where: 
MCS?Sn is the excess mortality rate in current smokers who switch to snus; 
MCS is the tobacco attributable mortality rate in current smokers; 
RRFS is the relative risk of tobacco attributable mortality in former smokers 
compared to current smokers based on years since quitting (Figure 1 to 3); 
and 
RRSn is the relative risk of tobacco attributable mortality in snus users who 
never smoked compared to current smokers (Table 4).  
 
Figure 6 shows age-specific mortality rates from all causes in a current male smoker 
who continues to smoke, a male smoker who quits tobacco use altogether at age 57 
and a male smoker who switches to snus at age 57. 
 
 
 
 
Figures 7 to 12 show survival plots of a cohort of smokers aged 35, 55 and 75 who 
continue to smoke, snus users aged 35, 55 and 75, smokers who quit tobacco use 
altogether at ages 35, 55 and 75 and smokers who switch to snus at ages 35, 55 
and 75. 
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Figure 6: Age-specific mortality rates of male smokers, smokers 
who switch to snus or quit all tobacco at age 57 
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Figure 8: Survival plot of female smokers, smokers who switch 
to snus or quit all tobacco at age 35 
Age
40 50 60 70 80 90 100
Pe
rc
en
ta
ge
 s
ur
vi
va
l
0.0
0.2
0.4
0.6
0.8
1.0
Smokers who continue smoking
Snus users who never smoked
Never smokers 
Smokers who quit at age 35
Smokers who switch to snus at age 35
 
Figure 7: Survival plot of male smokers, smokers who switch to 
snus or quit all tobacco at age 35 
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Figure 10: Survival plot of female smokers, smokers who switch 
to snus or quit all tobacco at age 55 
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Figure 9: Survival plot of male smokers, smokers who switch to 
snus or quit all tobacco at age 55 
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Figure 12: Survival plot of female smokers, smokers who switch 
to snus or quit all tobacco at age 75 
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Figure 11: Survival plot of male smokers, smokers who switch 
to snus or quit all tobacco at age 75 
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Health adjusted life expectancy (HALE) by smoking status 
 
Life tables, using the mortality rates in Figure 4, with the appropriate adjustments for 
stopping smoking or starting to use snus, were used to determine the remaining life-
expectancy for different sex and 5-year age (ages 35 to 80) cohorts by smoking 
status. We assume that age-specific mortality rates by smoking status in the year 
2000 are applicable to future cohorts as they age. Given that current smokers in 
Australia have similar ages of initiation, and thus exposure time (the main 
determinant of tobacco risk), this assumption is likely to hold reasonably well. 
 
Remaining life-expectancy was adjusted for severity-weighted disability due to both 
tobacco related and non-tobacco related causes. Non-tobacco related disability was 
applied as a function of age (Figure 13) and was determined from the Australian 
Burden of Disease Study.3  
 
 
 
To account for disability attributable to tobacco-related causes, a ratio of prevalent 
years lived with disability (YLD) to death for each cause in the year 20003 was used 
as an average population estimate of smoking-related disability proportionate to 
each death (Table 5). 
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Figure 13: Prevalent years lived with disability (YLD) for non-
tobacco related causes 
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Table 5: Ratio of prevalent years lived with disability to death for tobacco-
related causes in the year 2000 from the Australian Burden of Disease Study 
 Males Females 
Cause 35-44 45-54 55-64 65-74 75+ 35-44 45-54 55-64 65-74 75+ 
Lung Ca 0.9 1.3 1.4 1.0 0.7 2.5 1.9 1.9 1.2 0.7 
UA Ca 4.2 0.8 0.5 0.3 0.3 5.4 1.2 1.2 0.5 0.2 
Pancreas Ca 0.4 0.7 0.6 0.4 0.3 0.9 0.9 0.8 0.4 0.3 
Bladder Ca  6.2 3.4 3.6 6.6  1.3 2.5 3.9 2.3 
Kidney Ca 0.8 1.4 2.9 4.6 2.6  3.4 3.4 3.3 1.9 
COPD  59.8 30.6 6.8 2.0  54.4 14.8 5.3 3.5 
IHD 1.1 0.9 0.7 0.4 0.1 3.8 2.5 2.2 0.8 0.2 
Stroke 29.2 17.0 13.4 8.9 3.0 77.8 49.8 23.6 13.9 2.4 
Arterial disease  75.8 54.4 15.3 1.2  45.8 48.7 25.6 1.2 
Other CVD 6.1 5.4 4.6 2.5 1.5 9.1 5.7 4.0 2.6 1.6 
Other resp 159.7 162.4 42.4 32.1 20.4 316.2 272.1 135.9 51.4 10.9 
Ca Cancer; UA Upper Aerodigestive; COPD Chronic obstructive pulmonary disease; CVD Cardiovascular 
disease; IHD Ischemic heart disease; resp dis Respiratory disease 
 
Uncertainty assumptions  
 
Uncertainty intervals provide a range of values within which the true value of a 
parameter is likely to fall. Table 6 summarises the assumptions for each of the 
variables that were used to calculate the expected health adjusted life expectancies 
for each tobacco use category examined. Tables 2, 7 and 8 provide the point 
estimates and uncertainty intervals for each of these variables. The impact of 
uncertainty in these values on the main outcome measures was estimated by 
Monte-Carlo simulation (2000 iterations) using @RISK (Palisade Corporation). 
 
Table 6: Uncertainty Assumptions and Distributions 
Parameter Uncertainty 
Type of 
Distribution Reference 
Relative risk of lung cancer, upper aero-
digestive cancer, pancreatic cancer, kidney 
cancer, bladder cancer, ischemic heart 
disease, stroke, arterial disease, other CVD, 
COPD, and other respiratory mortality in 
smokers compared to never smokers  
95% 
confidence 
interval 
(Table 2) 
Triangular 7 
Tobacco-attributable mortality in snus users 
who never smoked compared to smokers  
+/- 25% 
(Table 7) 
Triangular Assumption 
Ratio of years lost due to disability to number 
of deaths for tobacco attributable disease  
+/- 25% 
(Table 8) 
Triangular Assumption 
 
 
Table 7: Uncertainty estimates of tobacco-attributable mortality in snus users 
who never smoked compared to smokers 
 Age 
Cause 35-49  ≥ 50  
Ischemic heart disease, stroke, arterial disease & 
other CVD  0.10 (0.08 - 0.13) 0.10 (0.08 - 0.13)
Upper aerodigestive, pancreas, bladder and kidney 
cancer  0.15 (0.11 - 0.19) 0.30 (0.23 - 0.38)
Lung cancer 0.02 (0.02 - 0.03) 0.03 (0.03 - 0.04)
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Table 8: Uncertainty Interval for ratio of years lost due to disability to 
number of deaths for tobacco attributable disease 
 Age 
Cause 35-44 45-54 55-64 65-74 75+ 
Males      
Lung Ca 0.9 (0.7-1.1) 1.3 (1.0-1.6) 1.4 (1.0-1.7) 1.0 (0.8-1.3) 0.7 (0.5-0.9) 
UA Ca 4.2 (3.2-5.3) 0.8 (0.6-1.0) 0.5 (0.3-0.6) 0.3 (0.2-0.4) 0.3 (0.2-0.4) 
Pancreas Ca 0.4 (0.3-0.4) 0.7 (0.5-0.9) 0.6 (0.4-0.7) 0.4 (0.3-0.5) 0.3 (0.3-0.4) 
Bladder Ca 0.0 (0.0-0.0) 6.2 (4.6-7.7) 3.4 (2.5-4.2) 3.6 (2.7-4.5) 6.6 (4.9-8.2) 
Kidney Ca 0.8 (0.6-1.0) 1.4 (1.1-1.8) 2.9 (2.2-3.6) 4.6 (3.5-5.8) 2.6 (2.0-3.3) 
COPD 0.0 (0.0-0.0) 59.8 (44.9-74.8) 30.6 (23.0-38.3) 6.8 (5.1-8.5) 2.0 (1.5-2.5) 
IHD 1.1 (0.8-1.4) 0.9 (0.6-1.1) 0.7 (0.5-0.8) 0.4 (0.3-0.5) 0.1 (0.1-0.2) 
Stroke 29.2 (21.9-36.5) 17.0 (12.7-21.2) 13.4 (10.1-16.8) 8.9 (6.7-11.2) 3.0 (2.3-3.8) 
Arterial 0.0 (0.0-0.0) 75.8 (56.8-94.7) 54.4 (40.8-68.1) 15.3 (11.5-19.1) 1.2 (0.9-1.5) 
Other CVD 6.1 (4.6-7.6) 5.4 (4.0-6.7) 4.6 (3.4-5.7) 2.5 (1.8-3.1) 1.5 (1.1-1.9) 
Other resp dis 160 (120-200) 162 (122-203) 42.4 (31.8-53.0) 32.1 (24.1-40.1) 20.4 (15.3-25.5) 
      
Females      
Lung Ca 2.5 (1.9-3.2) 1.9 (1.4-2.4) 1.9 (1.4-2.4) 1.2 (0.9-1.5) 0.7 (0.5-0.8) 
UA Ca 5.4 (4.0-6.7) 1.2 (0.9-1.5) 1.2 (0.9-1.5) 0.5 (0.4-0.6) 0.2 (0.1-0.2) 
Pancreas Ca 0.9 (0.7-1.1) 0.9 (0.7-1.1) 0.8 (0.6-0.9) 0.4 (0.3-0.5) 0.3 (0.2-0.3) 
Bladder Ca 0.0 (0.0-0.0) 1.3 (1.0-1.6) 2.5 (1.9-3.1) 3.9 (2.9-4.9) 2.3 (1.7-2.9) 
Kidney Ca 0.0 (0.0-0.0) 3.4 (2.6-4.3) 3.4 (2.6-4.3) 3.3 (2.5-4.1) 1.9 (1.4-2.3) 
COPD 0.0 (0.0-0.0) 54.4 (40.8-68.0) 14.8 (11.1-18.5) 5.3 (4.0-6.6) 3.5 (2.6-4.4) 
IHD 3.8 (2.8-4.7) 2.5 (1.9-3.2) 2.2 (1.6-2.7) 0.8 (0.6-1.0) 0.2 (0.1-0.2) 
Stroke 77.8 (58.4-97.3) 49.8 (37.3-62.2) 23.6 (17.7-29.5) 13.9 (10.4-17.4) 2.4 (1.8-3.0) 
Arterial 0.0 (0.0-0.0) 45.8 (34.4-57.3) 48.7 (36.5-60.9) 25.6 (19.2-32.0) 1.2 (0.9-1.5) 
Other CVD 9.1 (6.8-11.4) 5.7 (4.3-7.2) 4.0 (3.0-5.1) 2.6 (1.9-3.2) 1.6 (1.2-2.0) 
Other resp dis 316 (237-395) 272 (204-340) 136 (102-170) 51.4 (38.6-64.3) 10.9 (8.1-13.6) 
Ca Cancer; UA Upper Aerodigestive; COPD Chronic obstructive pulmonary disease; CVD Cardiovascular 
disease; IHD Ischemic heart disease; resp dis Respiratory disease 
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